Hyperspectral imaging as monitoring of cutaneous microcirculatory responsiveness in patients with sepsis.

• Conditions: A41.9; Sepsis, unspecified

• Registration Number: DRKS00029210
• Lead Sponsor: Klinik für Anästhesiologie und IntensivmedizinUniversitätsklinikum Essen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-12-22
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Written declaration of consent by the legal representative
- Inclusion according to the regulations of the consiliary physician procedure
- age > 18 years
- sepsis according to sepsis-3 definition
- invasive ventilation

Exclusion Criteria

- Age < 18 years
- Refusal to participate in the study
- Patient likely to be transferred from ICU within first 72 hours of study inclusion
- Palliative therapeutic approach
- Existing therapy goal limitation
- Death of the patient is already foreseeable or inevitable at study inclusion
- Dark skin type (methodological limitation for cutaneous hyperspectral imaging)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome measures are the correlations of the HSI parameters (StO2, NIR, or NPI, THI, and TWI) with the vasoactive-inotropic score (VIS).

Secondary Outcome Measures

Name	Time	Method
Secondary objective is to investigate the relationship between HSI data and severity of organ dysfunction using the sepsis-related organ failure assessment score (SOFA score), macrocirculatory paramaters, and established clinical parameters for systemic oxygen supply deficit include (e.g., blood lactate levels).